Schizophrenia Mortality: Barriers to Progress

  title={Schizophrenia Mortality: Barriers to Progress},
  author={M. Seeman},
  journal={Psychiatric Quarterly},
  • M. Seeman
  • Published 2019
  • Psychology, Medicine
  • Psychiatric Quarterly
Individuals with schizophrenia die, on average, 20 years before their peers, with ‘natural causes’ accounting for 80% of premature deaths. The aim of this narrative review is to address this phenomenon from the perspective of known factors that contribute to long life. The relevant literature from the last decade was searched in PubMed and Google Scholar databases. Four factors have been shown to be common to centarians, people who live to be a hundred: genes, life style behaviors that favor a… Expand
Schizophrenia and cancer.
The literature makes recommendations about surmounting barriers and also offers suggestions with respect to support and palliative care in advanced stages of cancer, including examples of effective collaboration between mental health and cancer care specialists. Expand
Women with Schizophrenia over the Life Span: Health Promotion, Treatment and Outcomes
A narrative review of treatment of women with schizophrenia at different periods of their life paying special attention to reproductive and post-reproductive stages suggests that menstrual cycle-dependent treatments may be a useful option for many women and that recommendations re contraceptive options need always to be part of care provision. Expand
Natural cause mortality of mental health consumers: A 10-year retrospective cohort study.
There is a critical need to close the life expectancy gap for consumers with mental illness through dedicated focus on reducing mortality risk due to modifiable clinical characteristics which lead to consumer mortality. Expand
Treatment patterns and appropriateness of antipsychotic prescriptions in patients with schizophrenia
Overall, a high level of inappropriateness in antipsychotic prescriptions was observed, and greater adherence to guidelines could maximize the benefits of antipsychotics medications while minimizing risk of adverse effects. Expand
Gut microbiota and microbiome in schizophrenia
A narrative review of studies addressing gut microbiota alterations in patients with schizophrenia that were published in the years 2019–2020 finds that findings from clinical trials do not support the use of probiotics as add-on treatments in schizophrenia. Expand
Association of the NOTCH4 gene polymorphism with schizophrenia in the Indian population
The findings of the study suggest that the NOTCH4 polymorphism is significantly associated with schizophrenia in Indian population and these SNPs might also have an important role in the symptomatology of the disease. Expand
Synonymous polymorphism rs201256011 in dopamine receptor type 2 gene is associated with schizophrenia and PANSS score in Pakistani population: A first report
Keeping in view the genetic diversity among populations and important role of DRD2 polymorphisms in schizophrenia, two of its SNPs rs1801028 and rs6277 in patients with schizophrenia from Pakistan were studied. Expand
mTOR Expression in Hippocampus and Prefrontal Cortex Is Downregulated in a Rat Model of Schizophrenia Induced by Chronic Administration of Ketamine
Ketamine at 60 mg/kg decreased the expression of mTOR protein in the brain of rats, which helps elucidate the mechanisms of ketamine-induced schizophrenia and provides novel insights for drug discovery and development. Expand


Trends in mortality in schizophrenia and their implications
A striking finding from this new Finnish study is the marked reduction in the proportion of patients with schizophrenia followed up over years with follow-up mortality data, which appears to indicate that the mortality gap is not widening in schizophrenia in some settings. Expand
Twenty-five year mortality of a community cohort with schizophrenia
People with schizophrenia have a mortality risk that is two to three times that of the general population, and most of the extra deaths are from natural causes. Expand
Premature Mortality Among Adults With Schizophrenia in the United States.
In a US national cohort of adults with schizophrenia, excess deaths from cardiovascular and respiratory diseases implicate modifiable cardiovascular risk factors, including especially tobacco use, which highlight threats posed by substance abuse. Expand
A widening longevity gap between people with schizophrenia and general population: A literature review and call for action
This review of eight longitudinal studies of mortality in schizophrenia found that the mean standardized mortality ratio (SMR), a measure of mortality rate in schizophrenia compared to the general population, increased 37%, from 2.2 in the pre- 1970s studies to 3.0 in the post-1970s reports. Expand
Mortality in people with psychotic disorders in Finland: A population-based 13-year follow-up study
The elevated mortality risk associated with NAP is only partly explained by socioeconomic factors, lifestyle, cardiometabolic comorbidities and inflammation, and smoking cessation should be prioritized in treatment of psychotic disorders. Expand
The dietary pattern of patients with schizophrenia: a systematic review.
OBJECTIVE People with schizophrenia show a high incidence of metabolic syndrome, which is associated with a high mortality from cardiovascular disease. The aetiology of the metabolic syndrome inExpand
Existential questions in schizophrenia: perception of patients and caregivers.
To develop a new type of health care in which both the consideration for the person with schizophrenia and their subjectivity are as important as biological treatment, health promotion strategies need to combat stigma and use mechanisms of occupational inclusion. Expand
Mortality in mental disorders: Are we approaching to close the gap respect to other medical specialties? The case of schizophrenia
Conclusions Although data on the effect of antipsychotics on mortality are encouraging, the field of psychiatry is still far from achieving results in line with what observed in other areas ofExpand
Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study
The findings indicate that cardiometabolic health risks in people with SSD may be more common than those reported in the general Hong Kong population and provide further support for the need to consider antipsychotic polypharmacy and higher doses of antipsychotics as factors that may contribute towards cardiometric risk in Chinese patients with SSD. Expand
Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis.
Estimates suggest that mental disorders rank among the most substantial causes of death worldwide, and efforts to quantify and address the global burden of illness need to better consider the role of mental disorders in preventable mortality. Expand